| Title | Author(s) | Year | View Count |  | Effect of atorvastatin on serum soluble receptor for advanced glycation end products in type 2 diabetes | Tam, HL; Shiu, SWM; Chow, WS; Wong, Y; Tan, KCB | 2008 | 151 |
 | Hypoadiponectinemia as a predictor for the development of hypertension: A 5-year prospective study | Chow, WS; Cheung, BMY; Tso, AWK; Xu, A; Wat, NMS; Fong, CHY; Ong, LHY; Tam, S; Tan, KCB; Janus, ED; Lam, TH; Lam, KSL | 2007 | 188 |
| Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans | Wang, Y; Lam, KSL; Kraegen, EW; Sweeney, G; Zhang, J; Tso, AWK; Chow, WS; Wat, NMS; Xu, JY; Hoo, RLC; Xu, A | 2007 | 200 |
| Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes | Tan, KCB; Chow, WS; Tso, AWK; Xu, A; Tse, HF; Hoo, RLC; Betteridge, DJ; Lam, KSL | 2007 | 145 |
| Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production | Hoo, RLC; Chow, WS; Yau, MH; Xu, A; Tso, AWK; Tse, HF; Fong, CHY; Tam, S; Chan, L; Lam, KSL | 2007 | 163 |
| Adipocyte fatty acid binding protein as a potential circulating metabolic hormone: clinical and functional studies. | Lam, KSL; Tso, AWK; Chow, WS; Hoo, RLC; Zhang, J; Lam, CW; Xu, A | 2007 | 70 |
| Innovative risk stratification model for high-risk diabetic patients in a tertiary referral centre – triage of the triaged | Wat, NMS; Tan, KCB; Chow, WS; Tse, PM; Wong, K; Leung, E; Hung, V; Leung, SK; Yee, A; Leung, CY; Lam, KSL | 2007 | 163 |
| PPAR-γ agonist induced-suppression of plasminogen activator inhibitor-1 production is mediated through adiponectin. | Hoo, RLC; Chow, WS; Yau, MH; Xu, A; Tse, HF; Tso, AWK; Fong, HY; Tam, S; Chan, L; Lam, KSL | 2007 | 68 |
| Adiponectin mediates the suppressive effect of rosiglitazone on PAI-1 production | Chow, WS; Hoo, RLC; Yau, MH; Xu, A; Tse, HF; Tso, AWK; Fong, HY; Tam, S; Chan, L; Lam, KSL | 2007 | 91 |
| Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans | Zhang, X; Yeung, CY; Wong, LC; Chow, WS; Xu, A; Lam, KSL | 2007 | 84 |
| Ppar-γ Agonist Induced-suppression Of Plasminogen Activator Inhibitor-1 Production Is Mediated Through Adiponectin. | Hoo, RLC; Chow, WS; Tse, HF; Fong, HY; Tam, S; Chan, LCB; Lam, KSL | 2007 | 78 |
| HDL dysfunction in obstructive sleep apnea | Tan, KCB; Chow, WS; Lam, JCM; Lam, B; Wong, WK; Tam, S; Ip, MSM | 2006 | 115 |
| Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. | Tan, KC; Shiu, SW; Chow, WS; Leng, L; Bucala, R; Betteridge, DJ | 2006 | 290 |
| Advanced glycation end products are increased in non-diabetic patients with obstructive sleep apnea but to a lesser degree than type 2 diabetic patients | Chow, WS; Tan, KCB; Lam, JCM; Lam, B; Bucala, R; Betteridge, DJ; Ip, MSM | 2006 | 77 |
| Adiponectin is predictive of changes in diastolic blood pressure over 5 years in Chinese women | Chow, WS; Tso, AWK; Ong, LHY; Wat, NMS; Xu, A; Fong, HY; Janus, ED; Lam, KSL | 2006 | 102 |
| C reactive protein to adiponectin ratio is superior to body mass index in the prediction of cardiovascular risk progression and the metabolic syndrome over 5 years in non-obese Chinese. | Tso, AWK; Wat, NMS; Xu, A; Chow, WS; Tam, S; Fong, HY; Janus, ED; Lam, KSL | 2006 | 103 |
| Hypoadiponectinaemia predicts the development of hypertension in Chinese. | Ong, LHY; Chow, WS; Tso, AWK; Wat, NMS; Xu, A; Fong, HY; Janus, ED; Lam, KSL | 2006 | 137 |
| Serum level of soluble receptor for advanced glcyation end products is associated with circulating advanced glycation end products in type 2 diabetes | Tan, KCB; Chow, WS; Shiu, SWM; Bucala, R; Betteridge, DJ | 2006 | 105 |
| Increased serum level of soluble receptor for advanced glycation end products in type 2 diabetic patients with nephropathy | Tan, KCB; Chow, WS; Shiu, SWM; Bucala, R; Betteridge, DJ | 2006 | 72 |
| Arterial stiffness and advanced glycation end products in type 2 diabetes mellitus | Tan, KCB; Shiu, SWM; Chow, WS; Wong, Y; Bucala, R; Betteridge, DJ | 2006 | 133 |
|
